0001104659-22-033392.txt : 20220314
0001104659-22-033392.hdr.sgml : 20220314
20220314170315
ACCESSION NUMBER: 0001104659-22-033392
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220310
FILED AS OF DATE: 20220314
DATE AS OF CHANGE: 20220314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Korbel Gregory Alan
CENTRAL INDEX KEY: 0001789032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 22737418
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
tm229119-4_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-03-10
0
0001781983
Aprea Therapeutics, Inc.
APRE
0001789032
Korbel Gregory Alan
535 BOYLSTON STREET
BOSTON
MA
02116
1
1
0
0
SVP, Chief Business Officer
Common Stock
2022-03-10
4
A
0
16000
0
A
31841
D
Common Stock
2022-03-10
4
F
0
1989
1.82
D
29852
D
Stock Option (right to Buy)
1.82
2022-03-10
4
A
0
72600
0
A
2032-03-10
Common Stock
72600
72600
D
These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units
Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
/s/ Scott M. Coiante, attorney-in-fact
2022-03-14